Faeth Therapeutics, Inc. (NASDAQ:FTH) — Market Cap & Net Worth
Market Cap & Net Worth: Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (NASDAQ:FTH) has a market capitalization of $783.82 Million ($783.82 Million) as of July 13, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10036 globally and #2699 in its home market, demonstrating a 52.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Faeth Therapeutics, Inc.'s stock price $36.16 by its total outstanding shares 25778754 (25.78 Million). Review Faeth Therapeutics, Inc. total liabilities to assess the company's total debt and financial obligations.
Faeth Therapeutics, Inc. Market Cap History: 2026 to 2026
Faeth Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $932.16 Million to $932.16 Million (0.00% CAGR).
Faeth Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Faeth Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FTH by Market Capitalization
Companies near Faeth Therapeutics, Inc. in the global market cap rankings as of July 13, 2026.
Key companies related to Faeth Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #429 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #549 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #567 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $485.39 |
| #429 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $664.52 |
| #549 | Argen-X | BR:ARGX | $49.55 Billion | €763.80 |
| #567 | UCB SA | BR:UCB | $47.34 Billion | €237.10 |
Faeth Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Faeth Therapeutics, Inc.'s market cap moved from $932.16 Million to $ 932.16 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $932.16 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 12th, 2026 the market cap of Faeth Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $783.82 Million USD |
| MoneyControl | $783.82 Million USD |
| MarketWatch | $783.82 Million USD |
| marketcap.company | $783.82 Million USD |
| Reuters | $783.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more